Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia - A prospective, randomized, double-blind trial
Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia - A prospective, randomized, double-blind trial
复制标题
DOI：
10.1161/01.cir.0000068312.21969.c8
复制
发表时间：
2003-05-20
期刊：
影响因子：
37.8
通讯作者：
Veltri, EP
中科院分区：
文献类型：
--
作者：
Ballantyne, CM;Houri, J;Veltri, EP
背景——尽管他汀类药物的疗效已得到证实，但许多患者并未达到推荐的低密度脂蛋白胆固醇 (LDL-C) 目标。促成因素可能是剂量不足、高剂量单药治疗不良反应的风险增加，以及现有药物组合的不耐受和不良反应的可能性增加。方法和结果-在一项双盲研究中，628 名基线 LDL-C 为 145 至 250 mg/dL、甘油三酯小于或等于 350 mg/dL 的患者被随机分配接受以下其中一种治疗，为期 12 周： 依折麦布（10毫克/天）；阿托伐他汀（10、20、40 或 80 毫克/天）；依折麦布 (10 mg) 加阿托伐他汀 (10、20、40 或 80 mg/d)；或安慰剂。主要疗效终点是依折麦布加阿托伐他汀联合治疗组与阿托伐他汀联合治疗组相比 LDL-C 降低百分比。与单用阿托伐他汀相比，依折麦布联合阿托伐他汀显着改善 LDL-C、HDL 胆固醇 (HDL-C)、甘油三酯、总胆固醇：HDL-C 和高敏 C 反应蛋白 (hs-CRP)（P
Background-Despite the established efficacy of statins, many patients do not achieve recommended LDL cholesterol (LDL-C) goals. Contributing factors may be inadequate dosing, increased risk for adverse effects with high-dose monotherapy, and increased potential for intolerance and adverse effects with combinations of available agents.Methods and Results-In a double-blind study, 628 patients with baseline LDL-C 145 to 250 mg/dL and triglycerides less than or equal to350 mg/dL were randomly assigned to receive 1 of the following for 12 weeks: ezetimibe (10 mg/d); atorvastatin (10, 20, 40, or 80 mg/d); ezetimibe (10 mg) plus atorvastatin (10, 20, 40, or 80 mg/d); or placebo. The primary efficacy end point was percentage reduction in LDL-C for pooled ezetimibe plus atorvastatin versus pooled atorvastatin treatment groups. Ezetimibe plus atorvastatin significantly improved LDL-C, HDL cholesterol (HDL-C), triglycerides, total cholesterol: HDL-C, and high-sensitivity C-reactive protein (hs-CRP) compared with atorvastatin alone (P